I am a
Home I AM A Search Login

Papers of the Week


2019 Nov


Eur Rev Med Pharmacol Sci


23


4 Suppl

Efficacy and tolerability of tapentadol prolonged release during rehabilitation: a prospective, observational study.

Authors

Orfei M, Milia P, Caserio M, Bagaphou TC
Eur Rev Med Pharmacol Sci. 2019 Nov; 23(4 Suppl):21-26.
PMID: 31755077.

Abstract

The treatment of chronic pain frequently combines pharmacologic and non-pharmacological options, and analgesia after surgery is of major importance. Tapentadol is both µ-opioid receptor agonist (with a 40% agonism on these receptors) and noradrenaline reuptake inhibitor, with similar analgesic efficacy to strong opioids, but fewer adverse effects. For these reasons, tapentadol may represent a valuable first choice option in the treatment of chronic, neuropathic, and mixed pain.